Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that results on the pharmacodynamic properties of emixustat hydrochloride in patients with geographic atrophy will be presented by Roger L. Novack, MD, PhD, Retina-Vitreous Associates Medical Group, Beverly Hills, California, during a podium session at the American Academy of Ophthalmology (AAO) 2014 Annual Meeting in Chicago, IL on Tuesday, October 21, 2014 at 10:46AM, CT.
Help employers find you! Check out all the jobs and post your resume.
